What does this research mean for the field?

Baxdrostat significantly improves blood pressure control in patients with uncontrolled or resistant hypertension, but is associated with an increased risk of hyperkalemia and other electrolyte disturbances. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the efficacy and safety of the selective aldosterone synthase inhibitor baxdrostat compared with placebo or standard care in patients with uncontrolled or resistant hypertension.

September 8, 2026Annals of Pharmacotherapy

Efficacy and Safety of Baxdrostat in Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials

View Full Paper

Ask AI

Bookmark

Authors

MBMuhammad Burhan ZSZain Ul Abideen Shahid MNMuhammad Abdullah Naveed

Discussion

Member takes

Overview

Systematic review and meta-analysis demonstrates improved blood pressure control with baxdrostat in resistant hypertension, indicating an effective therapy that requires close electrolyte monitoring.

Key Points

To evaluate the efficacy and safety of the selective aldosterone synthase inhibitor baxdrostat compared with placebo or standard care in patients with uncontrolled or resistant hypertension.
Conducted a PRISMA-compliant systematic review and meta-analysis searching PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov from inception through March 2026.
Synthesized randomized controlled trials using random-effects models to pool standardized mean differences (SMDs) and risk ratios (RRs), assessing evidence certainty via GRADE.
Baxdrostat significantly improved blood pressure control (p < .001) while causing modest reductions in serum sodium (SMD = -0.63; 95% CI = -0.80 to -0.47) and eGFR (SMD = -0.49; 95% CI = -0.65 to -0.34).
Patients receiving baxdrostat experienced higher serum potassium levels (SMD = 0.91; 95% CI = 0.77-1.05), a higher incidence of hyperkalemia (RR = 10.22; 95% CI = 4.22-24.73), and increased hyponatremia (RR = 2.90; 95% CI = 1.82-4.61), with no significant differences in serious adverse events or mortality.

Cite This Study

Burhan et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd79b58e84d0ff5b465d2 https://doi.org/10.1177/10600280261480672

View Full Paper

Ask AI

Bookmark

September 8, 2026Annals of Pharmacotherapy

Efficacy and Safety of Baxdrostat in Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials

View Full Paper

Ask AI

Bookmark

Authors

MBMuhammad Burhan ZSZain Ul Abideen Shahid MNMuhammad Abdullah Naveed

Discussion

Member takes

Overview

Systematic review and meta-analysis demonstrates improved blood pressure control with baxdrostat in resistant hypertension, indicating an effective therapy that requires close electrolyte monitoring.

Key Points

To evaluate the efficacy and safety of the selective aldosterone synthase inhibitor baxdrostat compared with placebo or standard care in patients with uncontrolled or resistant hypertension.
Conducted a PRISMA-compliant systematic review and meta-analysis searching PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov from inception through March 2026.
Synthesized randomized controlled trials using random-effects models to pool standardized mean differences (SMDs) and risk ratios (RRs), assessing evidence certainty via GRADE.
Baxdrostat significantly improved blood pressure control (p < .001) while causing modest reductions in serum sodium (SMD = -0.63; 95% CI = -0.80 to -0.47) and eGFR (SMD = -0.49; 95% CI = -0.65 to -0.34).
Patients receiving baxdrostat experienced higher serum potassium levels (SMD = 0.91; 95% CI = 0.77-1.05), a higher incidence of hyperkalemia (RR = 10.22; 95% CI = 4.22-24.73), and increased hyponatremia (RR = 2.90; 95% CI = 1.82-4.61), with no significant differences in serious adverse events or mortality.

Cite This Study

Burhan et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd79b58e84d0ff5b465d2 https://doi.org/10.1177/10600280261480672

View Full Paper

Ask AI

Bookmark